ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis

Documenti analoghi

• Nintedanib Lacks Efficacy in a Spirometry‐Confirmed and Bleomycin‐Induced Mouse Model of Idiopathic Pulmonary Fibrosis
  di: Jamal Bousamaki, et al.
  Pubblicazione: (2026)
• Regulated Cell Death in Idiopathic Pulmonary Fibrosis
  di: Xiaoyue Pan, et al.
  Pubblicazione: (2026)
• Widening Patient Engagement for Rare Disease Drug Trials: The Perspectives of Patients With Idiopathic Pulmonary Fibrosis on Participating in Clinical Drug Trials and Drug Trial Design
  di: Julia Frost, et al.
  Pubblicazione: (2025)
• Cell‐Surface LAMP1 is a Senescence Marker in Aging and Idiopathic Pulmonary Fibrosis
  di: Gabriel Meca‐Laguna, et al.
  Pubblicazione: (2025)
• Decoding Dysregulation of DNA Methylation in Epigenetics of Idiopathic Pulmonary Fibrosis
  di: Guorao Wu, et al.
  Pubblicazione: (2026)